ロード中...
Predicting response to vascular endothelial growth factor inhibitor and chemotherapy in metastatic colorectal cancer
BACKGROUND: Bevacizumab improves progression free survival (PFS) and overall survival (OS) in metastatic colorectal cancer patients however currently there are no biomarkers that predict response to this treatment. The aim of this study was to assess if differential protein expression can differenti...
保存先:
| 出版年: | BMC Cancer |
|---|---|
| 主要な著者: | , , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BioMed Central
2014
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4289341/ https://ncbi.nlm.nih.gov/pubmed/25428203 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-14-887 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|